Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial

The GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In chronic lymphocytic leukaemia (CLL) (GALACTIC) was a seamless phase II/III trial designed to test whether consolidation with obinutuzumab is safe and eradicates minimal residual disease (MRD) and, subsequently, whether this lea...

Descripción completa

Detalles Bibliográficos
Autores principales: Munir, Talha, Emmerson, Jake, Hockaday, Anna, Oughton, Jamie B., Howard, Dena, Phillips, David, Neilson, Jeff, Pemberton, Nicholas, Paneesha, Shankara, Kennedy, Ben, Rawstron, Andy, Hillmen, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematological Malignancy‐clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805170/
https://www.ncbi.nlm.nih.gov/pubmed/36017875
http://dx.doi.org/10.1111/bjh.18427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805170/
https://www.ncbi.nlm.nih.gov/pubmed/36017875
http://dx.doi.org/10.1111/bjh.18427

Ejemplares similares